[Skip to Navigation]
September 1963

Controlled Trial of Live Measles Vaccine: Effects of Age, History of Measles in Siblings, Prevaccine Antibody, and Human γ-Globulin on Symptomatic and Immune Responses

Author Affiliations

Lederle Laboratories, Pearl River, NY, Lot 2175-393.; Christopher M. Martin, MD, Department of Medicine, Seton Hall College of Medicine, Jersey City, NJ.; Associate Professor of Medicine (Dr. Martin); USPHS Trainee in Infectious Diseases (Dr. Manfredonia); Assistant Professor of Preventive Medicine and Community Health, Seton Hall College of Medicine (Dr. Webb); Research Fellow in Virology (Dr. Markham); Director of Clinical Investigation, Lederle Laboratories (Dr. Ruegsegger).; From the Division of Infectious Diseases, Department of Medicine, and the Department of Preventive Medicine and Community Health, Seton Hall College of Medicine; and the Lederle Laboratories.

Am J Dis Child. 1963;106(3):267-279. doi:10.1001/archpedi.1963.02080050269004

Numerous studies both in the United States and abroad 1-10 have fully confirmed the original demonstration11,12 of the efficacy of attenuated live measles virus vaccine derived from Enders' Edmonston strain.13 Of the several approaches to the problem of reducing the severity of symptomatic reactions to the vaccine without impairing effectiveness, that of concurrent administration of human γ-globulin has received the most attention and support.1,4-10

This report summarizes the results of a controlled trial of live measles vaccine, with and without human γ-globulin, in 134 children six months of age and older. The results permit definition and quantitative comparison of the relative effects of γ-globulin and of various host factors—age, history of measles in siblings, and prevaccine antibody—on the symptomatic and immune responses to the vaccine.

Although the results substantially confirm the efficacy of live measles vaccine, the data re-emphasize its unreliability in children under one year of

Add or change institution